Martins F, Sofiya L, Sykiotis GP, Lamine F, Maillard M, Fraga M, et al. Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance. Nat Rev Clin Oncol. 2019;16(9):563–80. https://doi.org/10.1038/s41571-019-0218-0.

Article  CAS  PubMed  Google Scholar 

Wei SC, Meijers WC, Axelrod ML, Anang NAS, Screever EM, Wescott EC, et al. A genetic mouse model recapitulates immune checkpoint inhibitor-associated myocarditis and supports a mechanism-based therapeutic intervention. Cancer Discov. 2021;11(3):614–25. https://doi.org/10.1158/2159-8290.CD-20-0856.

Article  CAS  PubMed  Google Scholar 

Patel RP, Parikh R, Gunturu KS, Tariq RZ, Dani SS, Ganatra S, et al. Cardiotoxicity of immune checkpoint inhibitors. Curr Oncol Rep. 2021;23(7):79. https://doi.org/10.1007/s11912-021-01070-6.

Article  PubMed  PubMed Central  Google Scholar 

Wang DY, Salem J-E, Cohen JV, Chandra S, Menzer C, Ye F, et al. Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysis. JAMA Oncol. 2018;4(12):1721. https://doi.org/10.1001/jamaoncol.2018.3923.

Article  PubMed  PubMed Central  Google Scholar 

Haanen J, Obeid M, Spain L, Carbonnel F, Wang Y, Robert C, et al. Management of toxicities from immunotherapy: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2022;33(12):1217–38. https://doi.org/10.1016/j.annonc.2022.10.001.

Article  CAS  PubMed  Google Scholar 

Haratani K, Hayashi H, Chiba Y, Kudo K, Yonesaka K, Kato R, et al. Association of immune-related adverse events with nivolumab efficacy in non–small-cell lung cancer. JAMA Oncol. 2018;4(3):374. https://doi.org/10.1001/jamaoncol.2017.2925.

Article  PubMed  Google Scholar 

Wang Y, Zou J, Li Y, Jiao X, Wang Y, Zhuo N, et al. Serological biomarkers predict immune-related adverse events and clinical benefit in patients with advanced gastrointestinal cancers. Front Immunol. 2022;13: 987568. https://doi.org/10.3389/fimmu.2022.987568.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Yasuda Y, Fujiwara R, Oguchi T, Komai Y, Numao N, Yamamoto S, et al. Prognostic significance of immune-related adverse events in metastatic renal cell carcinoma patients treated with immune-checkpoint-inhibitors. Cancer Diagn Progn. 2023;3(3):327–33. https://doi.org/10.21873/cdp.10219.

Article  PubMed  PubMed Central  Google Scholar 

Thompson LL, Nadelmann ER, Blum AE, Yoon J, Polyakov NJ, Kagan RD, et al. Patterns and prognostic significance of cutaneous immune-related adverse events in non-small cell lung cancer. Eur J Cancer. 2021;147:13–6. https://doi.org/10.1016/j.ejca.2021.01.022.

Article  PubMed  Google Scholar 

Larkin J, Chiarion-Sileni V, Gonzalez R, Grob J-J, Rutkowski P, Lao CD, et al. Five-year survival with combined nivolumab and ipilimumab in advanced melanoma. N Engl J Med. 2019;381(16):1535–46. https://doi.org/10.1056/NEJMoa1910836.

Article  CAS  PubMed  Google Scholar 

Reck M, Rodriguez-Abreu D, Robinson AG, Hui R, Csoszi T, Fulop A, et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med. 2016;375(19):1823–33. https://doi.org/10.1056/NEJMoa1606774.

Article  CAS  Google Scholar 

Motzer RJ, Tannir NM, McDermott DF, Aren Frontera O, Melichar B, Choueiri TK, et al. Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma. N Engl J Med. 2018;378(14):1277–90. https://doi.org/10.1056/NEJMoa1712126.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Burtness B, Harrington KJ, Greil R, Soulieres D, Tahara M, De Castro G, et al. Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study. Lancet. 2019;394(10212):1915–28. https://doi.org/10.1016/S0140-6736(19)32591-7.

Article  CAS  PubMed  Google Scholar 

Finn RS, Qin S, Ikeda M, Galle PR, Ducreux M, Kim T-Y, et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N Engl J Med. 2020;382(20):1894–905. https://doi.org/10.1056/NEJMoa1915745.

Article  CAS  PubMed  Google Scholar 

Oh D-Y, Ruth He A, Qin S, Chen L-T, Okusaka T, Vogel A, et al. Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer. NEJM Evid. 2022. https://doi.org/10.1056/EVIDoa2200015.

Article  Google Scholar 

Janjigian YY, Shitara K, Moehler M, Garrido M, Salman P, Shen L, et al. First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial. Lancet. 2021;398(10294):27–40. https://doi.org/10.1016/S0140-6736(21)00797-2.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Powles T, Park SH, Voog E, Caserta C, Valderrama BP, Gurney H, et al. Avelumab maintenance therapy for advanced or metastatic urothelial carcinoma. N Engl J Med. 2020;383(13):1218–30. https://doi.org/10.1056/NEJMoa2002788.

Article  CAS  PubMed  Google Scholar 

Baas P, Scherpereel A, Nowak AK, Fujimoto N, Peters S, Tsao AS, et al. First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial. Lancet. 2021;397(10272):375–86. https://doi.org/10.1016/S0140-6736(20)32714-8.

Article  CAS  PubMed  Google Scholar 

Salem J-E, Bretagne M, Abbar B, Leonard-Louis S, Ederhy S, Redheuil A, et al. Abatacept/ruxolitinib and screening for concomitant respiratory muscle failure to mitigate fatality of immune-checkpoint inhibitor myocarditis. Cancer Discov. 2023;13(5):1100–15. https://doi.org/10.1158/2159-8290.CD-22-1180.

Article  CAS  PubMed  Google Scholar 

Jiménez-Alejandre R, Ruiz-Fernández I, Martín P. Pathophysiology of immune checkpoint inhibitor-induced myocarditis. Cancers. 2022;14(18):4494. https://doi.org/10.3390/cancers14184494.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hu J-R, Florido R, Lipson EJ, Naidoo J, Ardehali R, Tocchetti CG, et al. Cardiovascular toxicities associated with immune checkpoint inhibitors. Cardiovasc Res. 2019;115(5):854–68. https://doi.org/10.1093/cvr/cvz026.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lyon AR, Yousaf N, Battisti NML, Moslehi J, Larkin J. Immune checkpoint inhibitors and cardiovascular toxicity. Lancet Oncol. 2018;19(9):e447–58. https://doi.org/10.1016/S1470-2045(18)30457-1.

Article  CAS  PubMed  Google Scholar 

Thompson JA, Schneider BJ, Brahmer J, Andrews S, Armand P, Bhatia S, et al. NCCN guidelines insights: management of immunotherapy-related toxicities, Version 1.2020. J Natl Compr Canc Netw. 2020;18(3):230–41. https://doi.org/10.6004/jnccn.2020.0012.

Article  CAS  PubMed  Google Scholar 

Velasco R, Villagran M, Jove M, Simo M, Vilarino N, Alemany M, et al. Encephalitis induced by immune checkpoint inhibitors: a systematic review. JAMA Neurol. 2021;78(7):864. https://doi.org/10.1001/jamaneurol.2021.0249.

Article  PubMed  Google Scholar 

Marini A, Bernardini A, Gigli GL, Valente M, Muniz-Castrillo S, Honnorat J, et al. Neurologic adverse events of immune checkpoint inhibitors: a systematic review. Neurology. 2021;96(16):754–66. https://doi.org/10.1212/WNL.0000000000011795.

Article  CAS  PubMed  Google Scholar 

Li Y, Zhang X, Zhao C. Guillain-Barré syndrome-like polyneuropathy associated with immune checkpoint inhibitors: a systematic review of 33 cases. BioMed Res Int. 2021;2021:1–17. https://doi.org/10.1155/2021/9800488.

Article  CAS  Google Scholar 

Sechi E, Zekeridou A. Neurologic complications of immune checkpoint inhibitors in thoracic malignancies. J Thorac Oncol. 2021;16(3):381–94. https://doi.org/10.1016/j.jtho.2020.11.005.

Article  CAS  PubMed  Google Scholar 

Vogrig A, Muniz-Castrillo S, Joubert B, Picard G, Rogemond V, Skowron F, et al. Cranial nerve disorders associated with immune checkpoint inhibitors. Neurology. 2021;96(6):e866–75. https://doi.org/10.1212/WNL.0000000000011340.

Article  CAS  PubMed  Google Scholar 

Spain L, Walls G, Julve M, O’Meara K, Schmid T, Kalaitzaki E, et al. Neurotoxicity from immune-checkpoint inhibition in the treatment of melanoma: a single centre experience and review of the literature. Ann Oncol. 2017;28(2):377–85. https://doi.org/10.1093/annonc/mdw558.

Article  CAS  PubMed  Google Scholar 

Dalakas MC. Neurological complications of immune checkpoint inhibitors: what happens when you ‘take the brakes off’ the immune system. Ther Adv Neurol Disord. 2018;11:175628641879986. https://doi.org/10.1177/1756286418799864.

Article  CAS  Google Scholar 

Thouvenin L, Olivier T, Banna G, Addeo A, Friedlaender A. Immune checkpoint inhibitor-induced aseptic meningitis and encephalitis: a case-series and narrative review. Ther Adv Drug Saf. 2021;12:204209862110047. https://doi.org/10.1177/20420986211004745.

Article  CAS  Google Scholar 

Müller-Jensen L, Zierold S, Versluis JM, Boehmerle W, Huehnchen P, Endres M, et al. Characteristics of immune checkpoint inhibitor-induced encephalitis and comparison with HSV-1 and anti-LGI1 encephalitis: a retrospective multicentre cohort study. Eur J Cancer. 2022;175:224–35. https://doi.org/10.1016/j.ejca.2022.08.009.

Article  CAS  PubMed